ICON Shareholders Vote in Favour of All Resolutions at its Annual General Meeting
July 24 2019 - 6:00AM
Business Wire
ICON plc (NASDAQ: ICLR), a global provider
of drug development solutions and services to the pharmaceutical,
biotechnology and medical device industries, today announced that
all resolutions at the Annual General Meeting of the Company (AGM)
held on July 23, 2019 (which resolutions had all been recommended
by the Board) were all duly passed by shareholders. These
resolutions were set out in the Notice of the AGM sent to
shareholders dated June 10, 2019 and are available on the ICON plc
website.
The final results of the voting are as follows:
RESOLUTION NUMBER
RESOLUTION
TOTAL NUMBER OF VOTES
VOTE FOR
VOTE AGAINST
VOTE WITHHELD
1.1
To re-elect Dr. John Climax
45,426,638
45,129,835
287,973
8,830
1.2
To re-elect Dr. Steve Cutler
45,426,638
45,254,223
163,617
8,798
1.3
To re-elect Professor William
Hall
45,426,638
44,903,508
514,140
8,990
2
To receive accounts and
reports
45,426,638
45,274,969
15,009
136,660
3
To authorise the fixing of the
auditors’ remuneration
45,426,638
42,524,937
2,895,529
6,172
4
To authorise the Company to allot
shares
45,426,638
44,465,330
951,583
9,725
5**
To disapply pre-emption
rights
45,426,638
43,247,089
2,157,812
21,737
6**
To disapply pre-emption rights
for funding capital investment or acquisitions
45,426,638
43,249,638
2,156,336
20,664
7**
To authorise the Company to make
market purchases of shares
45,426,638
45,231,479
36,310
158,849
8**
To authorise the price range at
which the Company can reissue shares it holds as treasury
shares
45,426,638
45,135,367
126,751
164,520
** Special Resolution. All resolutions are ordinary resolutions
unless otherwise stated.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, as well as
economic and global market conditions and other risks and
uncertainties detailed from time to time in SEC reports filed by
ICON, all of which are difficult to predict and some of which are
beyond our control. For these reasons, you should not place undue
reliance on these forward-looking statements when making investment
decisions. The word "expected" and variations of such words and
similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they
are made and we do not undertake any obligation to update publicly
any forward-looking statement, either as a result of new
information, future events or otherwise. More information about the
risks and uncertainties relating to these forward-looking
statements may be found in SEC reports filed by ICON, including its
Form 20-F, F-1, S-8 and F-3, which are available on the SEC's
website at http://www.sec.gov.
ICON plc is a global provider of drug development solutions and
services to the pharmaceutical, biotechnology and medical device
industries. The company specialises in the strategic development,
management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical
studies. With headquarters in Dublin, Ireland, ICON employed
approximately 14,400 employees in 98 locations in 40 countries as
at June 30, 2019. Further information is available at
www.iconplc.com.
Source: ICON plc
All at ICON.
ICON/ICLR-F
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190724005303/en/
Investor Relations 1 888 381 7923 or Brendan Brennan Chief
Financial Officer + 353 1 291 2000
Jonathan Curtain Vice President Corporate Finance and Investor
Relations + 353 1 291 2000
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ICON (NASDAQ:ICLR)
Historical Stock Chart
From Apr 2023 to Apr 2024